WO2005033143A1 - Methode de stabilisation d'anticorps et preparation d'anticorps de type solution stabilisee - Google Patents

Methode de stabilisation d'anticorps et preparation d'anticorps de type solution stabilisee Download PDF

Info

Publication number
WO2005033143A1
WO2005033143A1 PCT/JP2004/014903 JP2004014903W WO2005033143A1 WO 2005033143 A1 WO2005033143 A1 WO 2005033143A1 JP 2004014903 W JP2004014903 W JP 2004014903W WO 2005033143 A1 WO2005033143 A1 WO 2005033143A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
solution
formation
preparation
glycine
Prior art date
Application number
PCT/JP2004/014903
Other languages
English (en)
Japanese (ja)
Inventor
Yuji Ueno
Takashi Kayashita
Atsushi Ishihara
Masashi Nakakura
Kyoko Yamauchi
Original Assignee
Kyowa Hakko Kogyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34419308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005033143(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US10/574,016 priority Critical patent/US8496930B2/en
Priority to ES04773700T priority patent/ES2562912T5/es
Priority to AU2004277466A priority patent/AU2004277466C1/en
Priority to DK04773700.2T priority patent/DK1698640T4/da
Priority to SI200432297T priority patent/SI1698640T2/sl
Application filed by Kyowa Hakko Kogyo Co., Ltd. filed Critical Kyowa Hakko Kogyo Co., Ltd.
Priority to CA2540848A priority patent/CA2540848C/fr
Priority to PL04773700T priority patent/PL1698640T5/pl
Priority to EP04773700.2A priority patent/EP1698640B2/fr
Priority to JP2005514512A priority patent/JP4219932B2/ja
Publication of WO2005033143A1 publication Critical patent/WO2005033143A1/fr
Priority to HK06112681.3A priority patent/HK1090933A1/zh
Priority to US13/918,507 priority patent/US9011850B2/en
Priority to US14/661,510 priority patent/US10172790B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

L'objectif de l'invention est d'obtenir une méthode d'inhibition de la formation d'un agrégat soluble d'un anticorps dans une solution; une méthode d'inhibition de la formation d'un produit dégradé chimiquement; et une méthode de stabilisation d'un anticorps. L'objectif est également d'obtenir une préparation d'anticorps de type solution dans laquelle la formation d'un agrégat soluble est inhibée; une préparation d'anticorps de type solution dans laquelle la formation d'un produit dégradé chimiquement est inhibée; une préparation d'anticorps de type solution dans laquelle la formation d'un agrégat soluble, la formation d'un produit dégradé chimiquement et la formation d'un agrégat insoluble sont inhibées; un agent d'inhibition de la formation d'un agrégat soluble d'un anticorps; un agent d'inhibition de la formation d'un produit dégradé chimiquement d'un anticorps; et un stabilisant d'anticorps.
PCT/JP2004/014903 2003-10-01 2004-10-01 Methode de stabilisation d'anticorps et preparation d'anticorps de type solution stabilisee WO2005033143A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2005514512A JP4219932B2 (ja) 2003-10-01 2004-10-01 抗体の安定化方法及び安定化された溶液状抗体製剤
PL04773700T PL1698640T5 (pl) 2003-10-01 2004-10-01 Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu
AU2004277466A AU2004277466C1 (en) 2003-10-01 2004-10-01 Method of stabilizing antibody and stabilized solution-type antibody preparation
DK04773700.2T DK1698640T4 (da) 2003-10-01 2004-10-01 Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning.
SI200432297T SI1698640T2 (sl) 2003-10-01 2004-10-01 Postopek za stabiliziranje protitelesa in stabiliziran pripravek protitelesa tipa raztopina
US10/574,016 US8496930B2 (en) 2003-10-01 2004-10-01 Method of stabilizing antibody and stabilized solution-type antibody preparation
CA2540848A CA2540848C (fr) 2003-10-01 2004-10-01 Methode de stabilisation d'anticorps et preparation d'anticorps de type solution stabilisee
ES04773700T ES2562912T5 (es) 2003-10-01 2004-10-01 Procedimiento de estabilización de un anticuerpo y preparación de anticuerpo de tipo disolución estabilizada
EP04773700.2A EP1698640B2 (fr) 2003-10-01 2004-10-01 Methode de stabilisation d'anticorps et preparation d'anticorps de type solution stabilisee
HK06112681.3A HK1090933A1 (zh) 2003-10-01 2006-11-17 穩定抗體的方法及穩定化溶液狀抗體製劑
US13/918,507 US9011850B2 (en) 2003-10-01 2013-06-14 Method of stabilizing antibody and stabilized solution-type antibody preparation
US14/661,510 US10172790B2 (en) 2003-10-01 2015-03-18 Method of stabilizing antibody and stabilized solution-type antibody preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-343645 2003-10-01
JP2003343645 2003-10-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/574,016 A-371-Of-International US8496930B2 (en) 2003-10-01 2004-10-01 Method of stabilizing antibody and stabilized solution-type antibody preparation
US13/918,507 Continuation US9011850B2 (en) 2003-10-01 2013-06-14 Method of stabilizing antibody and stabilized solution-type antibody preparation

Publications (1)

Publication Number Publication Date
WO2005033143A1 true WO2005033143A1 (fr) 2005-04-14

Family

ID=34419308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/014903 WO2005033143A1 (fr) 2003-10-01 2004-10-01 Methode de stabilisation d'anticorps et preparation d'anticorps de type solution stabilisee

Country Status (16)

Country Link
US (3) US8496930B2 (fr)
EP (2) EP1698640B2 (fr)
JP (1) JP4219932B2 (fr)
KR (1) KR100911091B1 (fr)
CN (1) CN100522998C (fr)
AU (1) AU2004277466C1 (fr)
CA (1) CA2540848C (fr)
CY (1) CY1117215T1 (fr)
DK (1) DK1698640T4 (fr)
ES (1) ES2562912T5 (fr)
HK (1) HK1090933A1 (fr)
HU (1) HUE026793T2 (fr)
PL (1) PL1698640T5 (fr)
PT (1) PT1698640E (fr)
SI (1) SI1698640T2 (fr)
WO (1) WO2005033143A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016562A3 (fr) * 2005-07-29 2007-04-05 Amgen Inc Formulations inhibant l'agregation de proteines
JP2008540684A (ja) * 2005-05-19 2008-11-20 アムジェン インコーポレイテッド 抗体の安定性を増加させるための組成物および方法
JP2009534401A (ja) * 2006-04-21 2009-09-24 ノバルティス アーゲー 拮抗剤抗ｃｄ４０抗体薬学的組成物
JP2012528830A (ja) * 2009-06-04 2012-11-15 アルク アーゲー 少なくとも１つのアドレナリン作動性化合物を含む安定化された組成物
JP2013544763A (ja) * 2010-09-17 2013-12-19 バクスター、インターナショナル、インコーポレイテッド 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化
CN103772505A (zh) * 2013-12-18 2014-05-07 长春博迅生物技术有限责任公司 一种抗体试剂保存液
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US8895506B2 (en) 2006-12-14 2014-11-25 DePuy Synthes Products, LLC Protein stabilization formulations
JP2016525110A (ja) * 2013-07-19 2016-08-22 ヘクサル・アクチェンゲゼルシャフトＨｅｘａｌ ＡＧ バイオ医薬品の投与に関連した免疫応答を調節可能にする方法および製剤
WO2017170626A1 (fr) * 2016-03-30 2017-10-05 千寿製薬株式会社 Agent liquide aqueux

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US8496930B2 (en) * 2003-10-01 2013-07-30 Kyowa Hakko Kirin Co., Ltd Method of stabilizing antibody and stabilized solution-type antibody preparation
US7776331B1 (en) * 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
NZ580379A (en) 2007-03-29 2012-10-26 Abbott Lab Crystalline anti-human il-12 antibodies
NZ709704A (en) * 2007-11-30 2017-03-31 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
RU2497545C2 (ru) 2008-03-18 2013-11-10 Эбботт Лэборетриз Способ лечения псориаза (варианты)
CN102301235B (zh) * 2008-11-28 2014-11-19 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
JP2012526121A (ja) * 2009-05-04 2012-10-25 アボツト・バイオテクノロジー・リミテツド ヒト抗ｔｎｆアルファ抗体の安定した高蛋白質濃度製剤
SG179135A1 (en) * 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
EP3708190A1 (fr) 2010-02-26 2020-09-16 Novo Nordisk A/S Compositions contenant un anticorps stable
NZ602115A (en) 2010-03-01 2014-12-24 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
MX344727B (es) 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP6527697B2 (ja) 2013-01-28 2019-06-05 国立大学法人 熊本大学 タンパク質を安定化させたゲル状製剤
EP3374390A1 (fr) 2015-11-13 2018-09-19 Visterra, Inc. Compositions et méthodes pour traiter et prévenir la grippe
US20170240617A1 (en) * 2016-02-24 2017-08-24 Visterra, Inc. Formulations of antibody molecules to influenza virus
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
EP3946613A1 (fr) 2019-03-25 2022-02-09 Visterra, Inc. Compositions et méthodes pour traiter et prévenir la grippe
AU2020364436A1 (en) * 2019-10-11 2022-04-21 Dr. Reddy's Laboratories Limited Stable formulation of integrin antibody

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62194459A (ja) * 1986-02-21 1987-08-26 Sankyo Co Ltd 固相化試薬の安定化剤
JPH06189781A (ja) * 1992-12-25 1994-07-12 Mitsui Toatsu Chem Inc 培養液中の生理活性タンパク質の安定化方法
JPH07502497A (ja) * 1991-10-28 1995-03-16 ザ・ウエルカム・ファウンデーション・リミテッド 安定化抗体
JPH09500894A (ja) * 1993-07-30 1997-01-28 パストゥール メリユ セリュム エ ヴァサン 安定化された免疫グロブリンの調製物と、その調製方法
WO1999037329A1 (fr) * 1998-01-22 1999-07-29 Astrazeneca Ab Formulation pharmaceutique comprenant un anticorps et un tampon de citrate
WO2000066160A1 (fr) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
WO2003018635A1 (fr) 2001-08-31 2003-03-06 Kyowa Hakko Kogyo Co., Ltd. Anticorps greffes cdr humains et fragments de ces anticorps

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US421777A (en) * 1890-02-18 Straining-pot
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPS62244441A (ja) 1986-04-16 1987-10-24 Green Cross Corp:The 抗体固定化担体
DE3734923C1 (de) * 1987-10-15 1989-01-26 Biotest Pharma Gmbh Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt
JPH03504499A (ja) 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JP2966592B2 (ja) * 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
AU679913B2 (en) * 1992-04-30 1997-07-17 Millennium Pharmaceuticals, Inc. Stable polypeptide composition
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
ES2225874T3 (es) 1995-03-10 2005-03-16 Genentech, Inc. Activacion de receptor mediante gas.
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
EP1050307A1 (fr) 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. Antagonistes de CCR4 contre la septicémie
CA2383493C (fr) 1999-06-25 2010-08-10 Genentech, Inc. Traitement du cancer de la prostate a l'aide des anticorps anti-erbb2
ES2301491T3 (es) 1999-09-30 2008-07-01 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo humano de trasplante con region de determinacion de la complementariedad contra gangliosido gd3 y derivados del anticuerpo contra gangliosido gd3.
US20030124119A1 (en) * 1999-12-28 2003-07-03 Tadao Yamazaki Stable antibody compositions and injection preparations
PT1270595E (pt) 2000-03-03 2008-09-16 Kyowa Hakko Kogyo Kk Anticorpo recombinante de genes e os seus fragmentos
PT1314437E (pt) * 2000-08-11 2014-08-29 Chugai Pharmaceutical Co Ltd Preparações estabilizadas contendo anticorpo
WO2003063767A2 (fr) 2001-11-02 2003-08-07 Centocor Proteines du vrs, anticorps, compositions, procedes et utilisations
KR101080021B1 (ko) 2002-02-14 2011-11-04 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
US8496930B2 (en) * 2003-10-01 2013-07-30 Kyowa Hakko Kirin Co., Ltd Method of stabilizing antibody and stabilized solution-type antibody preparation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62194459A (ja) * 1986-02-21 1987-08-26 Sankyo Co Ltd 固相化試薬の安定化剤
JPH07502497A (ja) * 1991-10-28 1995-03-16 ザ・ウエルカム・ファウンデーション・リミテッド 安定化抗体
JPH06189781A (ja) * 1992-12-25 1994-07-12 Mitsui Toatsu Chem Inc 培養液中の生理活性タンパク質の安定化方法
JPH09500894A (ja) * 1993-07-30 1997-01-28 パストゥール メリユ セリュム エ ヴァサン 安定化された免疫グロブリンの調製物と、その調製方法
WO1999037329A1 (fr) * 1998-01-22 1999-07-29 Astrazeneca Ab Formulation pharmaceutique comprenant un anticorps et un tampon de citrate
WO2000066160A1 (fr) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
WO2003018635A1 (fr) 2001-08-31 2003-03-06 Kyowa Hakko Kogyo Co., Ltd. Anticorps greffes cdr humains et fragments de ces anticorps

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEN B. ET AL.: "Strategies to suppress aggregation of recombinant keratinocyte growth factor during liquid formulation developpment", vol. 83, no. 12, 1994, pages 1657 - 1661, XP002075996 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540684A (ja) * 2005-05-19 2008-11-20 アムジェン インコーポレイテッド 抗体の安定性を増加させるための組成物および方法
WO2007016562A3 (fr) * 2005-07-29 2007-04-05 Amgen Inc Formulations inhibant l'agregation de proteines
JP2009534401A (ja) * 2006-04-21 2009-09-24 ノバルティス アーゲー 拮抗剤抗ｃｄ４０抗体薬学的組成物
JP2013129673A (ja) * 2006-04-21 2013-07-04 Novartis Ag 拮抗剤抗ｃｄ４０抗体薬学的組成物
US8945564B2 (en) 2006-04-21 2015-02-03 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
US8895506B2 (en) 2006-12-14 2014-11-25 DePuy Synthes Products, LLC Protein stabilization formulations
JP2012528830A (ja) * 2009-06-04 2012-11-15 アルク アーゲー 少なくとも１つのアドレナリン作動性化合物を含む安定化された組成物
JP2012528831A (ja) * 2009-06-04 2012-11-15 アルク アーゲー 少なくとも１つのアドレナリン作動性化合物を含む安定化された組成物
US9155694B2 (en) 2009-06-04 2015-10-13 Alk Ag Stabilized composition comprising at least one adrenergic compound
JP2017071631A (ja) * 2010-09-17 2017-04-13 バクスアルタ ゲーエムベーハー 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化
JP2013544763A (ja) * 2010-09-17 2013-12-19 バクスター、インターナショナル、インコーポレイテッド 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化
KR101879885B1 (ko) * 2010-09-17 2018-07-18 박스알타 인코퍼레이티드 약산성 내지 중성 ｐｈ에서 히스티딘을 갖는 수성 제형을 통한 면역글로불린의 안정화
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
JP2016525110A (ja) * 2013-07-19 2016-08-22 ヘクサル・アクチェンゲゼルシャフトＨｅｘａｌ ＡＧ バイオ医薬品の投与に関連した免疫応答を調節可能にする方法および製剤
CN103772505A (zh) * 2013-12-18 2014-05-07 长春博迅生物技术有限责任公司 一种抗体试剂保存液
WO2017170626A1 (fr) * 2016-03-30 2017-10-05 千寿製薬株式会社 Agent liquide aqueux

Also Published As

Publication number Publication date
JPWO2005033143A1 (ja) 2007-11-15
HK1090933A1 (zh) 2007-01-05
CN1856507A (zh) 2006-11-01
US20150190507A1 (en) 2015-07-09
KR100911091B1 (ko) 2009-08-06
PT1698640E (pt) 2016-03-31
CN100522998C (zh) 2009-08-05
EP1698640B1 (fr) 2015-12-30
KR20060089227A (ko) 2006-08-08
EP3006463A1 (fr) 2016-04-13
US20130280248A1 (en) 2013-10-24
ES2562912T5 (es) 2020-02-18
HUE026793T2 (en) 2016-07-28
EP1698640A4 (fr) 2008-09-17
CY1117215T1 (el) 2017-04-05
US10172790B2 (en) 2019-01-08
US20070020255A1 (en) 2007-01-25
US8496930B2 (en) 2013-07-30
DK1698640T3 (en) 2016-02-15
SI1698640T2 (sl) 2019-08-30
AU2004277466A1 (en) 2005-04-14
PL1698640T3 (pl) 2016-05-31
AU2004277466B2 (en) 2010-04-01
US9011850B2 (en) 2015-04-21
AU2004277466C1 (en) 2022-06-23
EP1698640A1 (fr) 2006-09-06
JP4219932B2 (ja) 2009-02-04
SI1698640T1 (sl) 2016-03-31
EP1698640B2 (fr) 2019-06-19
PL1698640T5 (pl) 2019-12-31
ES2562912T3 (es) 2016-03-09
CA2540848A1 (fr) 2005-04-14
DK1698640T4 (da) 2019-09-02
CA2540848C (fr) 2012-12-11

Similar Documents

Publication Publication Date Title
JP4219932B2 (ja) 抗体の安定化方法及び安定化された溶液状抗体製剤
JP6469765B2 (ja) アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
KR101944211B1 (ko) 안정화 항체 함유 용액 제제
US9457089B2 (en) Highly concentrated aqueous protein solution with reduced viscosity
WO2007074880A1 (fr) Préparation stabilisatrice contenant des anticorps
AU2010338305A1 (en) Antibody formulation
KR102106914B1 (ko) Gm-csf를 중화하는 화합물을 포함하는 액체 제제
WO2004075913A1 (fr) Preparation stabilisee contenant une proteine
EP3797752A1 (fr) Formulation lyophilisée scellée dans un flacon en verre
US20180214556A1 (en) Aqueous composition comprising at least one protein and one solubilizing agent, preparation thereof and uses thereof
CA3235879A1 (fr) Formulation pharmaceutique comprenant un anticorps monoclonal anti-ox40
NZ617340B2 (en) Formulation for anti-?4?7 antibody
NZ617340A (en) Formulation for anti-α4β7 antibody

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480027187.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005514512

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2007020255

Country of ref document: US

Ref document number: 10574016

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2540848

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020067006311

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004277466

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004773700

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004277466

Country of ref document: AU

Date of ref document: 20041001

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004277466

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020067006311

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004773700

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10574016

Country of ref document: US